medigraphic.com
Órgano Oficial de la Asociación Mexicana de Infectología Pediátrica y la SLIPE.

2014, Number 107

<< Back

Rev Enfer Infec Pediatr 2014; 27.28 (107)

Vaccination against pertussis?

Hernández PM, González SN

Language: Spanish
References: 29
Page: 428-432
PDF size: 180.63 Kb.


ABSTRACT

Pertussis remains now a global public health problem that despite being virtually controlled through a universal vaccination has been an increase of cases in certain age groups, even in developed countries where high vaccination coverage reported. In Mexico due to disease epidemic cycles every three to four years. The average background incidence (non-epidemic years) reported between 1 and 2 confirmed cases per million population. To ensure adequate protection against pertussis vaccination recommendations exist for each age group with Tdap vaccine for adolescents and adults.


REFERENCES

  1. Moreno Espinosa S. Tosferina, enfermedad reemergente o desconocimiento de cambios en el comportamiento epidemiológico de una vieja enfermedad. Rev. de Enf. Inf. en Ped. 2012; 25: 119.

  2. Hernández Porras M. Tosferina en Manual para la aplicación y manejo de vacunas. 3ª. Edición. 2011; Pág. 43-50 editorial Nieto Editores.

  3. World Health Organization (WHO). Pertussis vaccines: WHO position paper.Weekly Epidemiol Rec. 2010; 85: 385-400.

  4. European Centre for Disease Prevention and Control (eCDC). EUVAC-NET.Petussis Surveillance Annual Report. 2009. Disponible en: www.euvac.net

  5. Hernández Porras M. Vacunar contra tosferina al adolescente? Rev. De Enf. Inf. En Ped. 2007; 21: 01.

  6. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination.Pediatr Infect Dis J. 2005; 24: S58-61.

  7. Moraga F, Roca J, Méndez C, Rodrigo C, Pineda V, Martínez A, et al. Epidemiologyand surveillance of pertussis among infantsin Catalonia, Spain, during 1997-2001.Pediatr Infect Dis J. 2005; 24: 510-3. 432 Revista de Enfermedades Infecciosas en Pediatría Actualidades en Vacunas

  8. American Academy of Pediatrics Committee on Infectious Diseases, Larry K Pickering. Red Book

  9. World Health Organization.Centers for Disease Control and Prevention.Vaccine preventable deaths and the global immunization vision and strategy, 2006-2015.MMWR. 2006; 55: 511-515.

  10. Plotkin S. Aims, scope and findings of the global pertussis initiative. PediatrInfectDis J. 2005; 24(5): S5-S6.

  11. Wood N, McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. PaediatrRespirRev 2008; 9: 201-211; quiz 211-212.

  12. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis among infants in the United States, 1980-1999.JAMA. 2003; 290: 2968-2975.

  13. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J. 2005; 24(5): S10-S18.

  14. Halperin SA. Pertussis immunization for adolescents: what are we waiting for? Can J Infect Dis. 2001; 12: 74-76.

  15. Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J. 2005; 24(6): S104-S108.

  16. Dirección General de Epidemiología. Manuales Simplificados Enfermedades Prevenibles por Vacunación. Secretaría de Salud. México. 2005.

  17. Guiso N, Wirsing von König CH, Forsyth K, Tan T, Plotkin SA. The Global Pertussis Initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11-12 January 2010. Vaccine. 2011; 29: 1115-1121.

  18. Sapián-López LA, Valdespino JL, Salvatierra B, Tapia-Conyer R, Gutiérrez G, Macedo J, et al. Seroepidemiology of whoopingcough in Mexico. Salud Publica Mex. 1992; 34: 177-185.

  19. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007; 26: 293-299.

  20. Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, Jennings CE, et al. Infant pertussis: who was the source? Pediatr Infect Dis J. 2004; 23: 985-989.

  21. Perret C, Viviani T, Peña A, Abarca K, Ferrés M. Source of infection in young infants hospitalized with Bordetella pertussis. Rev Med Chil. 2011; 139: 448-454.

  22. Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR RecommRep. 2006; 55(RR-3): 1-34.

  23. Ulloa-Gutierrez R, Hozbor D, Avila-Aguero ML, Caro J, Wirsing von König CH, Tan T, et al. The global pertussis initiative: meeting report from the Regional Latin America Meeting, Costa Rica, 5-6 December, 2008. HumVaccin. 2010; 6: 876-880.

  24. Updated recommendations for use of tetanus toxoid, reduced diphteria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months. AdvisoryCommitteeonImmunizationPractices (ACIP). CDC. 2011; 60: 1424-1426.

  25. Ulloa-Gutiérrez R. Estrategias actuales de vacunación contra tos ferina en niños y adultos. Acta Pediátrica Costarricense. 2009; 20: 81-87.

  26. Shakib JH, Ralston S, Raissy HH, Stoddard GJ, Edwards KM, Byington CL. Pertussis antibodies in postpartum women and their newborns. J Perinatol. 2010; 30: 93-97.

  27. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J ObstetGynecol. 2011; 204: 334.e1-e5.

  28. Van Rie A, WendelboeAM, Englund JA. Role of maternal pertussis antibodies in infants.PediatrInfectDis J. 2005; 24(5): S62-S65.

  29. Suárez IL, Herbas IR, Gómez AC. Tos ferina, un problema vigente de salud pública en México. Planteamineto de la necesidad para introducir una nueva vacuna. Bol. Med. Hosp. Infant. Mex. Vol.69 no.4 México jul/ago. 2012.




2020     |     www.medigraphic.com